These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9717120)

  • 21. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ovarian response to gonadotropin stimulation depends on the level of follicle stimulating hormone receptor on granulosa cells].
    Cai J; Gao HJ; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):372-4. PubMed ID: 16831356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization.
    Hofmann GE; Toner JP; Muasher SJ; Jones GS
    J In Vitro Fert Embryo Transf; 1989 Oct; 6(5):285-9. PubMed ID: 2517294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders.
    Padilla SL; Dugan K; Maruschak V; Shalika S; Smith RD
    Fertil Steril; 1996 Apr; 65(4):796-9. PubMed ID: 8654641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders.
    Wang PT; Lee RK; Su JT; Hou JW; Lin MH; Hu YM
    J Assist Reprod Genet; 2002 Jan; 19(1):1-6. PubMed ID: 11893009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do poor-responder patients undergoing IVF benefit from splitting and increasing the daily gonadotropin dose?
    Ezra O; Haas J; Nahum R; Maman E; Cohen Y; Segev-Zahav A; Orvieto R
    Gynecol Endocrinol; 2019 Oct; 35(10):890-893. PubMed ID: 31032673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients.
    Karande VC; Jones GS; Veeck LL; Muasher SJ
    Fertil Steril; 1990 Mar; 53(3):486-9. PubMed ID: 2106455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
    Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An increased initial follicle-stimulating hormone/luteinizing hormone ratio does not affect ovarian responses and the outcomes of in vitro fertilization.
    Benadiva CA; Ben-Rafael Z; Blasco L; Tureck R; Mastroianni L; Flickinger GL
    Fertil Steril; 1988 Nov; 50(5):777-81. PubMed ID: 3141220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates.
    Antman AM; Politch JA; Ginsburg ES
    Fertil Steril; 2002 Apr; 77(4):715-20. PubMed ID: 11937122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
    Nguyen TH; Lennard MS; Ghobadi C; Rostami-Hodjegan A; Ledger WL
    J Assist Reprod Genet; 2006; 23(11-12):427-31. PubMed ID: 17143744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Gonadotrophin dose and ovarian response: relations to the clinical outcome of in vitro fertilization and embryo transfer].
    Xiong XS; Chen SL; Sun L; Yin MN; Zhao EY; Song J
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):712-4. PubMed ID: 18504186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?
    Haas J; Zilberberg E; Machtinger R; Kedem A; Hourvitz A; Orvieto R
    Gynecol Endocrinol; 2015 Jan; 31(1):79-82. PubMed ID: 25223892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrafollicular endocrine milieu after addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization.
    Thuesen LL; Andersen AN; Loft A; Smitz J
    J Clin Endocrinol Metab; 2014 Feb; 99(2):517-26. PubMed ID: 24297796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12 298 trophectoderm biopsies.
    Irani M; Canon C; Robles A; Maddy B; Gunnala V; Qin X; Zhang C; Xu K; Rosenwaks Z
    Hum Reprod; 2020 May; 35(5):1082-1089. PubMed ID: 32348476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Do poor-responder patients benefit from increasing the daily gonadotropin dose from 300 to 450 IU during controlled ovarian hyperstimulation for IVF?].
    Haas J; Zilberberg E; Kedem A; Dar S; Orvieto R
    Harefuah; 2015 Feb; 154(2):114-7, 135. PubMed ID: 25856865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles.
    Fluker MR; Hooper WM; Yuzpe AA
    Fertil Steril; 1999 Feb; 71(2):294-301. PubMed ID: 9988401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal profiles in successful and unsuccessful implantation in IVF-ET after combined GnRH agonist/gonadotropin treatment for superovulation and hCG luteal support.
    Balasch J; Creus M; Fábregues F; Carmona F; Casamitjana R; Peñarrubia J; Rivera F; Vanrell JA
    Gynecol Endocrinol; 1995 Mar; 9(1):51-8. PubMed ID: 7793300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.